Effects of bifidobacterium longum and lactobacillus rhamnosuson gut microbiota in patients with lactose intolerance and persisting functional gastrointestinal symptoms: A randomised, double-blind, cross-over study

Nutrients

Volumn 11, Issue 4, 2019, Pages

  Vitellio, Paola ^a,b   Celano, Giuseppe ^a   Bonfrate, Leonilde ^b   Gobbetti, Marco ^c   Portincasa, Piero ^b   De Angelis, Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c FREE UNIVERSITY OF BOZEN BOLZANO   (Italy)

Author keywords

Lactose intolerance; Metabolome; Microbiome; Probiotics; Vitamin B6

Indexed keywords

2 NONENAL; 4 HYDROXYNONENAL; ACETIC ACID; BACTERIAL RNA; BUTANOL; HEXADECANOL; HEXANAL; INDOLIZINE; LIMONENE; PHENOL; PLACEBO; PROBIOTIC AGENT; PROPIONIC ACID; PYRIDOXINE; SATURATED FATTY ACID; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND; LACTASE; LACTOSE; VITAMIN B COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACTEROIDETES; BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; BLOATING; BRISTOL STOOL FORM SCALE; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTION TEST; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE FLORA; LACTASE DEFICIENCY; LACTOBACILLUS RHAMNOSUS; LACTOSE HYDROGEN BREATH TEST; LACTOSE INTOLERANCE; MALE; MASS FRAGMENTOGRAPHY; MEDSTYLE QUESTIONNAIRE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RNA EXTRACTION; VISUAL ANALOG SCALE; COMPLICATION; DIET; DYSBIOSIS; FECES; GROWTH, DEVELOPMENT AND AGING; INTESTINE; METABOLISM; MICROBIOLOGY; MIDDLE AGED;

ADULT; BIFIDOBACTERIUM LONGUM; CONSTIPATION; CROSS-OVER STUDIES; DIET; DOUBLE-BLIND METHOD; DYSBIOSIS; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINES; LACTASE; LACTOBACILLUS RHAMNOSUS; LACTOSE; LACTOSE INTOLERANCE; MALE; MIDDLE AGED; PROBIOTICS; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 85065114836     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu11040886     Document Type: Article

References (60)

1. Drossman, D.A. Functional Gastrointestinal Disorders: History, pathophysiology, clinical features and Rome IV. Gastroenterology 2016, 150, 1262-1279.
2. De Palma, G.; Collins, S.M.; Bercik, P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut. Microb. 2014, 5, 419-429.
3. Bonfrate, L.; Tack, J.; Grattagliano, I.; Cuomo, R.; Portincasa, P. Microbiota in health and irritable bowel syndrome: Current knowledge, perspectives and therapeutic options. Scand. J. Gastroenterol.2013, 48, 995-1009.
4. Portincasa, P.; Moschetta, A.; Baldassarre, G.; Altomare, D.F.; Palasciano, G. Pan-enteric dysmotility, impaired quality of life and alexithymia in a large group of patients meeting ROME II criteria for irritable bowel syndrome. World J. Gastroenterol. 2003, 9, 2293-2299.
5. Liebert, A.; Lopez, S.; Jones, B.L.; Montalva, N.; Gerbault, P.; Lau, W.; Thomas, M.G.; Bradman, N.; Maniatis, N.; Swallow, D.M. World-wide distributions of lactase persistence alleles and the complex effects of recombination and selection. Hum. Genet. 2017, 136, 1445-1453.
6. Wilson, K.; Hill, R.J. The role of food intolerance in functional gastrointestinal disorders in children.Aust. Fam. Phys. 2014, 43, 686-689.
7. Portincasa, P.; Di Ciaula, A.; Vacca, M.; Montelli, R.; Wang, D.Q.; Palasciano, G. Beneficial effects of oral tilactase on patients with hypolactasia. Eur. J. Clin. Investig. 2008, 38, 835-844.
8. Bonfrate, L.; Krawczyk, M.; Lembo, A.; Grattagliano, I.; Lammert, F.; Portincasa, P. Effects of dietary education, followed by a tailored fructose-restricted diet in adults with fructose malabsorption. Eur. J. Gastroenterol. Hepatol. 2015, 27, 785-796.
9. Yang, J.; Deng, Y.; Chu, H.; Cong, Y.; Zhao, J.; Pohl, D.; Misselwitz, B.; Fried, M.; Dai, N.; Fox, M. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2013, 11, 262-268.
10. Barr, S.I. Perceived lactose intolerance in adult Canadians: A national survey. Appl. Physiol. Nutr. Metab. 2013, 38, 830-835.
11. Farup, P.G.; Monsbakken, K.W.; Vandvik, P.O. Lactose malabsorption in a population with irritable bowel syndrome: Prevalence and symptoms. A case-control study. Scand. J. Gastroenterol. 2004, 39, 645-649.
12. The effects of probiotics in lactose intolerance: A systematic review. Crit. Rev. Food Sci. Nutr. 2018.
13. Tomasik, P.J.; Tomasik, P. Probiotics and prebiotics. Cereal Chem. 2003, 80, 113-117.
14. Hemarajata, P.; Versalovic, J. Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulation and neuromodulation. Ther. Adv. Gastroenterol. 2013, 6, 39-51.
15. Harper, A.; Naghibi, M.M.; Garcha, D. The role of bacteria, probiotics and diet in Irritable Bowel Syndrome. Foods 2018, 7, 13.
16. Wang, Y.; Wu, Y.; Wang, Y.; Xu, H.; Mei, X.; Yu, D.; Wang, Y.; Li, W. Antioxidant properties of probiotic bacteria. Nutrients 2017, 9, 521.
17. Honda, H.; Kataoka, F.; Nagaoka, S.; Kawai, Y.; Kitazawa, H.; Itoh, H.; Kimura, K.; Taketomo, N.; Yamazaki, Y.; Tateno, Y.; Saito, T. Beta-galactosidase, phospho-beta-galactosidase and phospho-beta-glucosidase activities in lactobacilli strains isolated from human faeces. Lett. Appl. Microbiol.2007, 45, 461-466.
18. Den Besten, G.; van Eunen, K.; Groen, A.K.; Venema, K.; Reijngoud, D.-J.; Bakker, B.M. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 2013, 54, 2325-2340.
19. Hurst, N.R.; Kendig, D.M.; Murthy, K.S.; Grider, J.R. The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon. Neurogastroenterol. Motil.2014, 26, 1586-1596.
20. Ligaarden, S.C.; Farup, P.G. Low intake of vitamin B6 is associated with irritable bowel syndrome symptoms. Nutr. Res. 2011, 31, 356-361.
21. Hellmann, H.; Mooney, S. Vitamin B6: A molecule for human health? Molecules 2010, 15, 442-459.
22. Mearin, F.; Lacy, B.E.; Chang, L.; Chey, W.D.; Lembo, A.J.; Simren, M.; Spiller, R. Bowel Disorders.Gastroenterology 2016.
23. Gasbarrini, A.; Corazza, G.R.; Gasbarrini, G.; Montalto, M.; Di Stefano, M.; Basilisco, G.; Parodi, A.; Usai-Satta, P.; Vernia, P.; Anania, C, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: The Rome Consensus Conference. Aliment. Pharmacol. Ther. 2009, 29, 1-49.
24. Di Stefano, M.; Missanelli, A.; Miceli, E.; Strocchi, A.; Corazza, G.R. Hydrogen breath test in the diagnosis of lactose malabsorption: Accuracy of new versus conventional criteria. J. Lab. Clin. Med.2004, 144, 313-318.
25. Thompson, D.G.; O’Brien, J.D.; Hardie, J.M. Influence of the oropharyngeal microflora on the measurement of exhaled breath hydrogen. Gastroenterology 1986, 91, 853-860.
26. Payne, D.L.; Welsh, J.D.; Claypool, P.L. Breath hydrogen (H2) response to carbohydrate malabsorption after exercise. J. Lab. Clin. Med. 1983, 102, 147-150.
27. Sofi, F.; Abbate, R.; Gensini, G.F.; Casini, A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: An updated systematic review and meta-analysis. Am. J. Clin. Nutr.2010, 92, 1189-1196.
28. Bonfrate, L.; Scaccianoce, G.; Palasciano, G.; Ben-Chetrit, E.; Portincasa, P. A novel cluster of patients with Familial Mediterranean Fever (FMF) in southern Italy (J COVER). Eur. J. Clin. Investig.2017, 47, 622-629.
29. Lewis, S.J.; Heaton, K.W. Stool form scale as a useful guide to intestinal transit time. Scand. J. Gastroenterol. 1997, 32, 920-924.
30. De Angelis, M.; Piccolo, M.; Vannini, L.; Siragusa, S.; De Giacomo, A.; Serrazzanetti, D.I.; Cristofori, F.; Guerzoni, M.E.; Gobbetti, M.; Francavilla, R. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS ONE 2013, 8, e76993.
31. Klindworth, A.; Pruesse, E.; Schweer, T.; Peplies, J.; Quast, C.; Horn, M.; Glockner, F.O. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res. 2013, 41, e1.
32. Chao, A.; Bunge, J. Estimating the number of species in a stochastic abundance model. Biometrics 2002, 58, 531-539.
33. Tallarida, R.J.; Murray, R.B. Manual of Pharmacologic Calculations with Computer Programs; Springer: New York, NY, USA, 1987.
34. Arnold, J.; Simpson, J.; Roach, J.; Bruno-Barcena, J.; Azcarate-Peril, M. Prebiotics for Lactose Intolerance: Variability in galacto-oligosaccharide utilization by intestinal Lactobacillus rhamnosus.Nutrients 2018, 10, 1517.
35. Szilagyi, A.; Ishayek, N. Lactose Intolerance, dairy avoidance, and treatment options. Nutrients 2018,10, 1994.
36. Nolan-Clark, D.; Tapsell, L.C.; Hu, R.; Han, D.Y.; Ferguson, L.R. Effects of dairy products on Crohn’s Disease Symptoms are influenced by fat content and disease location but not lactose content or disease activity status in a New Zealand population. J. Am. Diet. Assoc. 2011, 111, 1165-1172.
37. Mishkin, S. Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease. Am. J. Clin. Nutr. 1997, 65, 564-567.
38. Pal, S.; Woodford, K.; Kukuljan, S.; Ho, S. Milk Intolerance, beta-casein and lactose. Nutrients 2015,7, 7285-7297.
39. Jianqin, S.; Leiming, X.; Lu, X.; Yelland, G.W.; Ni, J.; Clarke, A.J. Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows’ milk. Nutr. J. 2015, 15, 35.
40. Collado, M.C.; Gueimonde, M.; Sanz, Y.; Salminen, S. Adhesion properties and competitive pathogen exclusion ability of bifidobacteria with acquired acid resistance. J. Food Prot. 2006, 69, 1675-1679.
41. Agustina, R.; Lukito, W.; Firmansyah, A.; Suhardjo, H.N.; Murniati, D.; Bindels, J. The effect of early nutritional supplementation with a mixture of probiotic, prebiotic, fiber and micronutrients in infants with acute diarrhea in Indonesia. Asia Pac. J. Clin. Nutr. 2007, 16, 435-442.
42. Zhu, Y.; Zheng, X.; Cong, Y.; Chu, H.; Fried, M.; Dai, N.; Fox, M. Bloating and distention in irritable bowel syndrome: The role of gas production and visceral sensation after lactose ingestion in a population with lactase deficiency. Am. J. Gastroenterol. 2013, 108, 1516-1525.
43. Riezzo, G.; Orlando, A.; D’Attoma, B.; Linsalata, M.; Martulli, M.; Russo, F. Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: Improvement in symptoms and bowel habit in functional constipation. Benef. Microbes 2018, 9, 51-60.
44. Yuce, O.; Kalayci, A.G.; Comba, A.; Eren, E.; Caltepe, G. Lactose and Fructose Intolerance in Turkish children with Chronic Abdominal Pain. Ind. Pediatr. 2016, 53, 394-397.
45. Use of a Novel Probiotic Formulation to Alleviate Lactose Intolerance Symptoms—A Pilot Study. Probiotics Antimicrob. Proteins 2019.
46. Rosenberg, J.; Ischebeck, T.; Commichau, F.M. Vitamin B6 metabolism in microbes and approaches for fermentative production. Biotechnol. Adv. 2017, 35, 31-40.
47. Arola, H.; Tamm, A. Metabolism of lactose in the human body. Scand. J. Gastroenterol. Suppl. 1994,202, 21-25.
48. Azcarate-Peril, M.A.; Ritter, A.J.; Savaiano, D.; Monteagudo-Mera, A.; Anderson, C.; Magness, S.T.; Klaenhammer, T.R. Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals. Proc. Natl. Acad. Sci. USA 2017, 114, E367-E375.
49. De Angelis, M.; Vannini, L.; Di Cagno, R.; Cavallo, N.; Minervini, F.; Francavilla, R.; Ercolini, D.; Gobbetti, M. Salivary and fecal microbiota and metabolome of celiac children under gluten-free diet.Int. J. Food Microbiol. 2016, 239, 125-132.
50. Setoyama, H.; Imaoka, A.; Ishikawa, H.; Umesaki, Y. Prevention of gut inflammation byBifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect. 2003, 5, 115-122.
51. Pakdaman, M.N.; Udani, J.K.; Molina, J.P.; Shahani, M. Erratum to: The effects of the DDS-1 strain ofLactobacillus on symptomatic relief for lactose intolerance—A randomized, double-blind, placebo-controlled, crossover clinical trial. Nutr. J. 2016, 15, 83.
52. Vipperla, K.; O’Keefe, S.J. The microbiota and its metabolites in colonic mucosal health and cancer risk. Nutr. Clin. Pract. 2012, 27, 624-635.
53. Thorburn, A.W.; Storlien, L.H.; Jenkins, A.B.; Khouri, S.; Kraegen, E.W. Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am. J. Clin. Nutr. 1989, 49, 1155-1163.
54. Portincasa, P.; Lembo, A.; De Bari, O.; Di Palo, D.M.; Maggio, A.; Cataldo, I.; Calamita, G. The role of dietary approach in irritable bowel syndrome. Curr. Med. Chem. 2017, 24, 1-8.
55. Portincasa, P.; Bonfrate, L.; de Bari, O.; Lembo, A.; Ballou, S. Irritable bowel syndrome and diet.Gastroenterol. Rep. 2017, 5, 11-19.
56. Arora, T.; Sharma, R. Fermentation potential of the gut microbiome: Implications for energy homeostasis and weight management. Nutr. Rev. 2011, 69, 99-106.
57. Nicholson, J.K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-gut microbiota metabolic interactions. Science 2012, 336, 1262-1267.
58. Fukuda, S.; Toh, H.; Hase, K.; Oshima, K.; Nakanishi, Y.; Yoshimura, K.; Tobe, T.; Clarke, J.M.; Topping, D.L.; Suzuki, T, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011, 469, 543-547.
59. Vernocchi, P.; Del Chierico, F.; Putignani, L. Gut microbiota profiling: Metabolomics based approach to unravel compounds affecting human health. Front. Microbiol. 2016, 7, 1144.
60. Moens, F.; Van den Abbeele, P.; Basit, A.W.; Dodoo, C.; Chatterjee, R.; Smith, B.; Gaisford, S. A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro. Int. J. Pharm. 2019, 555, 1-10.